PURPOSE: To prospectively examine alterations in working memory (WM) -associated brain activation related to breast cancer and treatment by using functional magnetic resonance imaging. PATIENTS AND METHODS: Patients treated with chemotherapy (CTx+; n = 16) or without chemotherapy (CTx-; n = 12) and healthy controls (n = 15) were scanned during an n-back task at baseline (after surgery but before radiation, chemotherapy, and/or antiestrogen treatment), 1 month after completion of chemotherapy (M1), and 1 year later (Y1), or at yoked intervals for CTx- and controls. SPM5 was used for all image analyses, which included cross-sectional between-group and group-by-time interaction and longitudinal within-group analyses, all using a statistical threshold of 0.001. RESULTS: At baseline, patients with cancer showed increased bifrontal and decreased left parietal activation compared with controls. At M1, both cancer groups showed decreased frontal hyperactivation compared with controls, with increased hyperactivation at Y1. These cross-sectional findings were confirmed by group-by-time interaction analyses, which showed frontal activation decreases from baseline to M1 in patients compared with controls. Within-group analyses showed different patterns of longitudinal activation change by treatment group (CTx+ or CTx-), with prominent alterations in the frontal lobes bilaterally. CONCLUSION: Significant frontal lobe hyperactivation to support WM was found in patients with breast cancer. Superimposed on this background, patients showed decreased frontal activation at M1, with partial return to the previously abnormal baseline at Y1. These functional changes correspond to frontal lobe regions where we previously reported structural changes in this cohort and provide prospective, longitudinal data that further elucidate mechanisms underlying cognitive effects related to breast cancer and its treatment.
PURPOSE: To prospectively examine alterations in working memory (WM) -associated brain activation related to breast cancer and treatment by using functional magnetic resonance imaging. PATIENTS AND METHODS: Patients treated with chemotherapy (CTx+; n = 16) or without chemotherapy (CTx-; n = 12) and healthy controls (n = 15) were scanned during an n-back task at baseline (after surgery but before radiation, chemotherapy, and/or antiestrogen treatment), 1 month after completion of chemotherapy (M1), and 1 year later (Y1), or at yoked intervals for CTx- and controls. SPM5 was used for all image analyses, which included cross-sectional between-group and group-by-time interaction and longitudinal within-group analyses, all using a statistical threshold of 0.001. RESULTS: At baseline, patients with cancer showed increased bifrontal and decreased left parietal activation compared with controls. At M1, both cancer groups showed decreased frontal hyperactivation compared with controls, with increased hyperactivation at Y1. These cross-sectional findings were confirmed by group-by-time interaction analyses, which showed frontal activation decreases from baseline to M1 in patients compared with controls. Within-group analyses showed different patterns of longitudinal activation change by treatment group (CTx+ or CTx-), with prominent alterations in the frontal lobes bilaterally. CONCLUSION: Significant frontal lobe hyperactivation to support WM was found in patients with breast cancer. Superimposed on this background, patients showed decreased frontal activation at M1, with partial return to the previously abnormal baseline at Y1. These functional changes correspond to frontal lobe regions where we previously reported structural changes in this cohort and provide prospective, longitudinal data that further elucidate mechanisms underlying cognitive effects related to breast cancer and its treatment.
Authors: T W McAllister; A J Saykin; L A Flashman; M B Sparling; S C Johnson; S J Guerin; A C Mamourian; J B Weaver; N Yanofsky Journal: Neurology Date: 1999-10-12 Impact factor: 9.910
Authors: Heather A Wishart; Andrew J Saykin; Laura A Rabin; Robert B Santulli; Laura A Flashman; Stephen J Guerin; Alexander C Mamourian; Dorothy R Belloni; C Harker Rhodes; Thomas W McAllister Journal: Am J Psychiatry Date: 2006-09 Impact factor: 18.112
Authors: C E Gleason; T W Schmitz; T Hess; R L Koscik; M A Trivedi; M L Ries; C M Carlsson; M A Sager; S Asthana; S C Johnson Journal: Neurology Date: 2006-12-12 Impact factor: 9.910
Authors: Kristine A Donovan; Paul B Jacobsen; Brent J Small; Pamela N Munster; Michael A Andrykowski Journal: J Pain Symptom Manage Date: 2008-05-20 Impact factor: 3.612
Authors: Kerstin Hermelink; Michael Untch; Michael P Lux; Rolf Kreienberg; Thomas Beck; Ingo Bauerfeind; Karin Münzel Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: Lei Wang; Alexandra C Apple; Matthew P Schroeder; Anthony J Ryals; Joel L Voss; Darren Gitelman; Jerry J Sweet; Zeeshan A Butt; David Cella; Lynne I Wagner Journal: Cancer Date: 2015-10-20 Impact factor: 6.860
Authors: Alexandra M Gaynor; Denise Pergolizzi; Yesne Alici; Elizabeth Ryan; Katrazyna McNeal; Tim A Ahles; James C Root Journal: Brain Stimul Date: 2020-04-27 Impact factor: 8.955
Authors: Brenna C McDonald; Susan K Conroy; Dori J Smith; John D West; Andrew J Saykin Journal: Brain Behav Immun Date: 2012-05-18 Impact factor: 7.217
Authors: M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Debra E Lyon; Ronald Cohen; Huaihou Chen; Debra L Kelly; Angela Starkweather; Hyo-Chol Ahn; Colleen K Jackson-Cook Journal: J Cancer Res Clin Oncol Date: 2016-04-21 Impact factor: 4.553
Authors: Andrew J Saykin; Michiel B de Ruiter; Brenna C McDonald; Sabine Deprez; Daniel H S Silverman Journal: Brain Imaging Behav Date: 2013-12 Impact factor: 3.978
Authors: D D Correa; J C Root; R Baser; D Moore; K K Peck; E Lis; T B Shore; H T Thaler; A Jakubowski; N Relkin Journal: Brain Imaging Behav Date: 2013-12 Impact factor: 3.978
Authors: Kah Poh Loh; Michelle C Janelsins; Supriya G Mohile; Holly M Holmes; Tina Hsu; Sharon K Inouye; Meghan S Karuturi; Gretchen G Kimmick; Stuart M Lichtman; Allison Magnuson; Mary I Whitehead; Melisa L Wong; Tim A Ahles Journal: J Geriatr Oncol Date: 2016-07-05 Impact factor: 3.599